Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Trial Profile

A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EU-TREAT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 18 Apr 2019 Results assessing clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes published in the Diabetic Medicine
    • 16 Mar 2019 Results of a post-hoc analysis published in the Advances in Therapy
    • 26 Jun 2018 Results evaluating the effectiveness of degludec after switching from insulin glargine 100 units/mL (glargine U100), under routine care, presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top